Hidradenitis Suppurativa Pipeline Insight
DelveInsight’s, “Hidradenitis Suppurativa - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Hidradenitis Suppurativa Understanding
Hidradenitis Suppurativa: Overview
Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis majorly affecting areas of skin containing pilosebaceous glands. HS is also known as acne inversa or Verneuilles disease. The symptoms of hidradenitis suppurativa ranges from mild to severe. It causes a mixture of boil-like lumps, blackheads, cysts, scarring and channels in the skin that leak pus. Smoking, obesity, and overweight are environmental risk factors in HS development. Diagnosis of Hidradenitis suppurativa is done through clinical features. The severity of the disease can be characterized on a number of scales, the most commonly used being the Hurley staging system. Management of Hidradenitis suppurativa includes topical and systemic therapies in addition to lifestyle advice and psychosocial modifications but often the disease will recur and treatment will need to be escalated. Several comorbidities have been associated with HS, most notably inflammatory bowel disease, cardiovascular disease, and psychiatric diseases.
"Hidradenitis Suppurativa - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hidradenitis Suppurativa pipeline landscape is provided which includes the disease overview and Hidradenitis Suppurativa treatment guidelines. The assessment part of the report embraces, in depth Hidradenitis Suppurativa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hidradenitis Suppurativa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Hidradenitis Suppurativa R&D. The therapies under development are focused on novel approaches to treat/improve Hidradenitis Suppurativa.
Hidradenitis Suppurativa Emerging Drugs Chapters
This segment of the Hidradenitis Suppurativa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hidradenitis Suppurativa Emerging Drugs
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The drug is in Phase III clinical development for the treatment of psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. In September 2020, the FDA and EMA accepted UCB’s biologics license application (BLA) for bimekizumab for adults with moderate to severe plaque psoriasis.
Secukinumab (Cosentyx) is a fully humanized, monoclonal anti-IL-17A antibody. This biological therapy is indicated for the treatment of Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, Plaque psoriasis and Psoriatic arthritis. The drug is in Phase III clinical development for the treatment of Hidradenitis suppurativa.
Further product details are provided in the report……..
Hidradenitis Suppurativa: Therapeutic Assessment
This segment of the report provides insights about the different Hidradenitis Suppurativa drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hidradenitis Suppurativa
There are approx. 25+ key companies which are developing the therapies for Hidradenitis Suppurativa. The companies which have their Hidradenitis Suppurativa drug candidates in the most advanced stage, i.e. Phase III include, Novartis.
DelveInsight’s report covers around 25+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Hidradenitis Suppurativa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hidradenitis Suppurativa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hidradenitis Suppurativa drugs.
Hidradenitis Suppurativa Report Insights
- Hidradenitis Suppurativa Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Hidradenitis Suppurativa Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hidradenitis Suppurativa drugs?
- How many Hidradenitis Suppurativa drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hidradenitis Suppurativa?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hidradenitis Suppurativa therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hidradenitis Suppurativa and their status?
- What are the key designations that have been granted to the emerging drugs?